101
|
Abstract
AIM: To investigate the state of infection, replication site, pathogenicity and clinical significance of transfusion transmitted virus (TTV) in patients with hepatitis, especially in patients of unknown etiology.
METHODS: Liver tissues taken from 136 cases of non-A non-G hepatitis were tested for TT virus antigen and nucleic acid by in situ hybridization (ISH) and nested-polymerase chain reaction (PCR). Among them, TT virus genome and its complemental strand were also detected in 24 cases of autopsy liver and extrahepatic tissues with ISH. Meanwhile, TTV DNA was detected in the sera of 187 hepatitis patients by nested-PCR. The pathological and clinical data of the cases infected with TTV only were analyzed.
RESULTS: In liver, the total positive rate of TTV DNA was 32.4% and the positive signals were located in the nuclei of hepatocytes. In serus, TTV DNA was detected in 21.4% cases of hepatitis A-G, 34.4% of non-A non-G hepatitis and 15% of healthy donors. The correspondence rate of TTV DNA detection between liver tissue with ISH and sera with PCR was 63.2% and 89.3% in the same liver tissues by ISH and by PCR, respectively. Using double-strand probes and single-strand probes designed to detect TTV genome, the correspondence rate of TTV DNA detected in liver and extrahepatic tissues was 85.7%. Using single-strand probes, TTV genome could be detected in liver and extrahepatic tissues by PCR, but its complemental strands (replication strands) could be observed only in livers. The liver function of most cases infected with TTV alone was abnormal and the liver tissues had different pathological damage such as ballooning, acidophilia degeneration, formation of apoptosis bodies and focus of necrosis, but the inflammation in the lobule and portal area was mild.
CONCLUSION: The positive rate of TTV DNA among cases of hepatitis was higher than that of donors, especially in patients with non-A non-G hepatitis, but most of them were coinfected with other hepatitis viruses. TTV can infect not only hepatocytes, but also extrahepatic tissues. However, the chief replication place may be liver. The infection of TTV may have some pathogenicity. Although the pathogenicity is comparatively weak, it can still damage the liver tissues. The lesions in acute hepatitis (AH) and chronic hepatitis (CH) are mild, but in severe hepatitis (SH), it can be very serious and cause liver function failure, therefore, we should pay more attention to TTV when studying the possible pathogens of so-called “Liver hepatitis of unknown etiology”.
Collapse
Affiliation(s)
- Zhong-Jie Hu
- Department of Pathology, Beijing You'an Hospital, 8 You'an Men Wai, Beijing 100054, China.
| | | | | | | | | | | | | |
Collapse
|
102
|
Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Fölsch UR, Schmidt WE. Prevalence of and risk factors for hepatitis G (HGV) infection in haemodialysis patients: a multicentre study. Nephrol Dial Transplant 2002; 17:271-5. [PMID: 11812878 DOI: 10.1093/ndt/17.2.271] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Hepatitis G virus (HGV) or GB-virus type C (GBV-C) is, like hepatitis C, a blood-borne virus and a member of the family of flaviviridae. HGV is distributed globally and is present in the volunteer blood donor population. Thus, for epidemiological reasons, HGV is of interest in haemodialysis patients, who are at risk of parenterally transmitted infections. The aim of the present investigation was to assess the prevalence of HGV by antibody testing and HGV-RNA determination by PCR. METHODS The study was performed in haemodialysis units of the Patienten-Heim-Versorgung, an organization of haemodialysis units throughout Germany. A total of 2796 out of 3042 patients (92%) from 43 haemodialysis units were enrolled prospectively in the trial. Liver function tests were performed and epidemiologic data were obtained to evaluate risk factors for HGV in haemodialysis patients. RESULTS Antibodies against HGV were detected in 485 patients (17.5%). Viraemia was seen in 380 out of 1935 patients tested (19.6%). Fifty-eight patients (3.0%) were positive for both antibodies and HGV-RNA. Using a standard questionnaire in 1717 out of the 2786 patients, it was found that more than five blood transfusions increased the risk of HGV infection significantly (P<0.05). There was no association found between HGV infection and the length of time on haemodialysis. CONCLUSION HGV is common in German haemodialysis patients but, in contrast to other parenterally transmitted viruses, there is no further risk for new infections during haemodialysis, except for patients who have received several blood transfusions.
Collapse
Affiliation(s)
- Holger Hinrichsen
- First Department of Medicine, Christian-Albrechts-University, Schittenhelmstrasse 12, D-24105 Kiel, Germany.
| | | | | | | | | | | |
Collapse
|
103
|
Bilski B, Wysocki J. [Viral hepatitis as a disease with occupational etiology]. Med Pr 2002; 52:211-9. [PMID: 11712484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023] Open
Abstract
This paper reviews the literature and discusses the occupational background and conditions of hepatitis. There are known three hepatitis viruses (HAV, HBV and HCV) with proved transmission through occupational contacts. In addition, occupation-related infections HDV and HGV, are probable or possible. Current diagnostic and epidemiological data as well as suggestions concerning the prevention of occupational hepatitis are also presented. A concept of work ability of health-care workers infected with HBV and HCV is discussed.
Collapse
Affiliation(s)
- B Bilski
- Katedry Profilaktyki Zdrowotnej Akademii Medycznej im. K. Marcinkowskiego w Poznaniu
| | | |
Collapse
|
104
|
Shan YS, Lee PC, Wang JR, Tsai HP, Sung CM, Jin YT. Fibrosing cholestatic hepatitis possibly related to persistent parvovirus B19 infection in a renal transplant recipient. Nephrol Dial Transplant 2001; 16:2420-2. [PMID: 11733638 DOI: 10.1093/ndt/16.12.2420] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Y S Shan
- Department of Surgery, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | | | | | | | | | | |
Collapse
|
105
|
Abstract
Every year, thousands of outdoor trekkers worldwide visit high-altitude (>2500 m) destinations. Although high-altitude areas per se do not harbor any specific agents, it is important to know the pathogens encountered in the mountains to be better able to help the ill sojourner at high altitude. These are the same pathogens prevalent in the surrounding lowlands, but various factors such as immunomodulation, hypoxia, physiological adaptation, and harsh environmental stressors at high altitude may enhance susceptibility to these pathogens. Against this background, various gastrointestinal, respiratory, dermatological, neurological, and other infections encountered at high altitude are discussed. Because there are few published data on infections at high altitude, this review is largely anecdotal and based on personal experience.
Collapse
Affiliation(s)
- B Basnyat
- Nepal International Clinic/Himalaya Rescue Association, Department of Human Physiology, Tribhuvan University, Kathmandu, Nepal.
| | | | | |
Collapse
|
106
|
Foschini MP, Morandi L, Macchia S, DalMonte PR, Pession A. TT virus-related acute recurrent hepatitis. Histological features of a case and review of the literature. Virchows Arch 2001; 439:752-5. [PMID: 11787846 DOI: 10.1007/s004280100467] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
TT virus is a recently discovered virus, of which the pathogenetic potential is still uncertain. The present paper describes the histopathological features of a case of TT virus-related acute recurrent hepatitis. The patient is a 28-year-old woman with no history of drug or alcohol abuse, presenting with repeated episodes of hypertransaminasemia evidenced during the last 4 years. No other markers of viral or autoimmune disease were found. On histological analysis, the liver parenchyma showed a preserved architecture. The histological features were those of a mild acute hepatitis. The clinicopathological findings suggest th
Collapse
Affiliation(s)
- M P Foschini
- Department of Oncology, Section of Pathology, University of Bologna, Italy.
| | | | | | | | | |
Collapse
|
107
|
Stiefelhagen P. [Viral hepatitis. A diagnostic challenge]. MMW Fortschr Med 2001; 143 Suppl:107-16; quiz 117-8. [PMID: 11797591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
|
108
|
Abraham P, Radhakrishnan S, Raghuraman S, Viswanathan T, Daniel D, Sitaram U, Sridharan G. GB virus-C/hepatitis G virus and transfusion-transmitted virus infection in blood donors in a tertiary care hospital in south India. Vox Sang 2001; 81:264-5. [PMID: 11904004 DOI: 10.1046/j.1423-0410.2001.00109.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
109
|
Grassi M, Mammarella A, Sagliaschi G, Granati L, Musca A, Traditi F, Pezzella M. Persistent hepatitis G virus (HGV) infection in chronic hemodialysis patients and non-B, non-C chronic hepatitis. Clin Chem Lab Med 2001; 39:956-60. [PMID: 11758610 DOI: 10.1515/cclm.2001.154] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Three groups of patients have been studied longitudinally for 24 months to analyze the role of hepatitis G virus (HGV) in hepatic disease. Group 1 consisted of 50 patients with non-B, non-C chronic hepatitis, group 2 consisted of 44 hemodialyzed patients, and group 3 consisted of 50 healthy blood donors. The presence of HGV RNA was detected by both reverse transcription-polymerase chain reaction (RT-PCR) and capillary zone electrophoresis (CZE). At the baseline visit the HGV RNA was detected in seven out of 50 patients with non-B, non-C chronic hepatitis, in two out of 44 hemodialyzed patients, and in three out of 50 healthy blood donors. HGV-infected hemodialyzed patients and HGV viremic blood donors had serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels within normal limits. During the follow-up period the two HGV-positive hemodialyzed patients and the three infected healthy blood donors did not show any sign of hepatic disease. There were no significant differences between HGV-positive patients in the three groups at the beginning and at the end of the follow-up. No considerable deterioration of general health conditions was observed on the basis of clinical and laboratory data in HGV-positive chronic hepatitis patients. Finally, HGV does not seem to be responsible for hepatic disease.
Collapse
Affiliation(s)
- M Grassi
- Department of Medical Therapy, University of Rome La Sapienza, Italy
| | | | | | | | | | | | | |
Collapse
|
110
|
Klusonová H, Plísková L, Palicka V, Fixa P. [Prevalence of viral hepatitis G infection in hemodialysis patients and coinfection with viral hepatitis B and C]. Vnitr Lek 2001; 47:678-81. [PMID: 11789005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
The group of infectious agents causing viral hepatitis was extended by another virus the detection of which was published in 1995. This virus is described as virus of hepatitis G (HGV) or GBV-C virus and is included among RNA viruses family Flaviviridae. Detection of HGV is based on reverse transcription with subsequent amplification of the viral nucleic acid by means of a polymerase chain reaction. The authors examined sera of 82 chronically haemodialyzed patients incl. 22 (26.8%) HGV RNA positive ones, whereby coinfection with HBV was proved in 3 specimens (13%). In 6 HGV RNA positive samples anti-HCV positivity was found (27%), incl. one sample where HCV RNA positivity was proved (4.5%). Raised transaminase activity was found only in three patients with HGV RNA positivity (13.6%). From the presented results ensues that haemodialyzed patients are a high risk group for HGV infection.
Collapse
Affiliation(s)
- H Klusonová
- UK Praha, Farmaceutická fakulta, Hradec Králové
| | | | | | | |
Collapse
|
111
|
Kondili LA, Chionne P, Dettori S, Badolato MC, Grosso A, Vania A, Rapicetta M. GB virus C/hepatitis G virus exposure in Italian pediatric and young adult thalassemic patients. Infection 2001; 29:219-21. [PMID: 11545484 DOI: 10.1007/s15010-001-9172-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND The aim was to estimate the prevalence and the persistence of GB virus C/hepatitis G virus (GBV-C/HGV) exposure markers in a group at high risk for transfusion-transmitted agents. PATIENTS AND METHODS Serum samples from 37 thalassemic patients were screened for GBV-C/HGV RNA by reverse transcription PCR (RT-PCR) and for antibodies to the envelope protein E2 of GBV-C/HGV (anti-E2). RESULTS AND DISCUSSION GBV-C/HGV RNA and anti-E2 were detected in 13 (35%) and 12 (32%) sera, respectively. Contemporary presence of both markers was found in one patient. GBV-C/HGV exposure was found in 24 patients (64.8%). Mean levels of liver enzymes were similar in both exposed and unexposed GBV-C/HGV groups. 33 out of 35 patients showed no change in GBV-C/HGV RNA and anti-E2 status in sera taken 6 months apart. The rate of persistent infection was 92.3% and the anti-E2 seroconversion rate was 23% for sera taken at least 6 months apart. The temporal overlap between anti-E2 seroconversion and loss of detectable GBV-C/HGV RNA may last more than 6 months.
Collapse
Affiliation(s)
- L A Kondili
- Virology Laboratory, Istituto Superiore di Sanità, Rome, Italy
| | | | | | | | | | | | | |
Collapse
|
112
|
Abstract
The relationship of viral hepatitis and body piercing has been investigated in 12 research studies published between 1974 and 1997. Because there are often a large number of unknowns regarding the cause of viral hepatitis, most of the studies were conducted to identify multiple risk factors for hepatitis. Eight of the 12 studies identified percutaneous exposure, including body piercing and ear piercing, as a risk factor for viral hepatitis. Six studies found that hepatitis seropositivity was significantly associated with ear piercing. Conclusions indicate that evidence is sufficient to institute public health education along with regulation of the body-piercing industry. Recent research has found a significant increase in legislative efforts to regulate body piercing. Little research has focused directly on body piercing as a specific risk factor for viral hepatitis. Further research in this area is necessary to increase the understanding of hepatitis transmission by body piercing.
Collapse
Affiliation(s)
- M O Hayes
- University of New Hampshire, School of Health and Human Services, Durham, USA
| | | |
Collapse
|
113
|
Abstract
The pathogenesis of autoimmune liver disease and autoimmunity associated with chronic viral hepatitis remains poorly understood. One of the major hurdles to a deeper understanding of these pathological processes is the absence of clearly defined inductive mechanisms, which, if identified and characterised, could guide clinical strategies for their prevention or allow therapeutic intervention. Molecular mimicry leading to crossreactive autoimmune responses has gained strong experimental support in the past decade. A fundamental premise of this hypothesis is the involvement of a mimicking environmental trigger. In view of the numerous viral and bacterial agents epidemiologically linked to autoimmune liver diseases, we and others have proposed molecular mimicry to be an important mechanism in these diseases. We also propose similar crossreactive mechanisms to operate in the generation of autoimmunity in viral hepatitis. This review focuses on molecular mimicry at the level of the B-cell, as few data on T-cell crossreactivity in liver disease are thus far available.
Collapse
Affiliation(s)
- D P Bogdanos
- Immunology Group, Institute of Hepatology, University College London Medical School, London, UK
| | | | | |
Collapse
|
114
|
Tasso L, Castagnola E, Lo Giudice C, Torre F, Micalizzi C, Picciotto A, Giacchino R. Prospective evaluation of primary infection due to HCV, HGV or TTV in children with newly diagnosed neoplasia. Haematologica 2001; 86:761-2. [PMID: 11454533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023] Open
|
115
|
Kimura H, Nagasaka T, Hoshino Y, Hayashi N, Tanaka N, Xu JL, Kuzushima K, Morishima T. Severe hepatitis caused by Epstein-Barr virus without infection of hepatocytes. Hum Pathol 2001; 32:757-62. [PMID: 11486177 DOI: 10.1053/hupa.2001.25597] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Although hepatitis is a common feature of primary Epstein-Barr virus (EBV) infection, severe liver injury is rare and its pathogenesis is unclear. A previously healthy girl developed severe hepatitis with prolonged jaundice. Serologic examination showed that she had primary infection with EBV. An extremely high Epstein-Barr viral load was observed in her peripheral blood. The viral load decreased in parallel with symptomatic improvement. Histologic examinations showed spotty necrosis of the liver parenchyma and infiltration by CD8(+) T cells. The CD8(+) T cells, not hepatocytes, were positive for EBV. Possible mechanisms of viral hepatitis without infection of hepatocytes are discussed.
Collapse
MESH Headings
- Antigens, Viral/analysis
- CD8-Positive T-Lymphocytes/pathology
- CD8-Positive T-Lymphocytes/virology
- DNA, Viral/analysis
- Epstein-Barr Virus Infections/blood
- Epstein-Barr Virus Infections/pathology
- Epstein-Barr Virus Infections/virology
- Female
- Hepatitis, Viral, Human/blood
- Hepatitis, Viral, Human/etiology
- Hepatitis, Viral, Human/pathology
- Hepatocytes/pathology
- Hepatocytes/virology
- Herpesvirus 4, Human/genetics
- Herpesvirus 4, Human/immunology
- Herpesvirus 4, Human/isolation & purification
- Humans
- Immunoenzyme Techniques
- In Situ Hybridization
- Infant
- Liver/pathology
- Liver/virology
- Polymerase Chain Reaction/methods
- RNA, Viral/analysis
- Viral Load
Collapse
Affiliation(s)
- H Kimura
- Departments of Pediatrics, Clinical Pathology, and Health Science, Nagoya University School of Medicine; and the Laboratory of Viral Oncology, Aichi Cancer Research Institute, Nagoya, Japan
| | | | | | | | | | | | | | | |
Collapse
|
116
|
Lazzarini Z. An analysis of ethical issues in prescribing and dispensing syringes to injection drug users. Health Matrix Clevel 2001; 11:85-128. [PMID: 11345679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Affiliation(s)
- Z Lazzarini
- University of Connecticut Health Center, USA
| |
Collapse
|
117
|
Burris S, Lurie P, Ng M. Harm reduction in the health care system: the legality of prescribing and dispensing syringes to drug users. Health Matrix Clevel 2001; 11:5-64. [PMID: 11345676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Affiliation(s)
- S Burris
- Temple University School of Law, USA
| | | | | |
Collapse
|
118
|
Abstract
Despite several morphologic and functional changes that have been described in the aging liver, most relevant studies fail to identify a significant age-related deficit in liver function in humans. One of the important age-related changes is a decrease in regenerative capacity, which may partly explain the impaired recovery after severe viral and toxic injury in the elderly. Nevertheless, livers from older subjects are used successfully for transplantation. Substantial morbidity and mortality in the elderly is attributable to liver diseases, and the number of patients older than 65 years of age with chronic liver disease is increasing rapidly. Although there are no liver diseases specific to advanced age, the presentation, clinical course and management of liver diseases in the elderly may differ in important respects from those of younger individuals.
Collapse
Affiliation(s)
- A Regev
- Division of Hepatology, Center for Liver Diseases, University of Miami School of Medicine, Miami, Florida, USA.
| | | |
Collapse
|
119
|
Abstract
A new DNA virus, referred to as SEN virus (SEN V), has been isolated and is associated with blood-product transfusion and possibly Non A to Non E hepatitis. We performed a cross-sectional analysis of SEN V in liver transplant recipients at our center. Polymerase chain reaction was used to test for 2 genotypes of SEN V (SEN V:C/H and SEN V:D) in 58 unselected patients. Comparisons were made between SEN V--positive and SEN V--negative groups in terms of age, time posttransplantation, indications for transplantation, serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, and cytomegalovirus and Epstein-Barr virus status. Thirty of 58 transplant recipients (51.7%) were SEN V positive; 15.5% were positive for SEN V:C/H, 24.1% for SEN:D, and 12.1% for both strains. No significant differences were found based on primary indication for transplantation, including hepatitis C virus (HCV). Of the 14 of 21 patients with HCV seropositivity and HCV reinfection, 79% were positive for SEN V (P =.02). There was no difference in the proportion of patients with abnormal serum ALT and/or AST levels. A trend for the SEN V--positive group to have a greater mean ALT level (82 v 41 U/L; P =.067) was attributable to the subgroup with HCV recurrence because there was no difference in mean ALT levels (34.9 v 34.5 U/L; P =.968) in non--HCV-infected transplant recipients. Even in the subgroup (n = 14) with recurrent HCV, there was no statistically significant difference in mean ALT levels (140 v 105 U/L; P =.665). Age and cytomegalovirus or Epstein-Barr virus status were not significantly different between the 2 groups, but a significant difference in posttransplantation time was noted (16.8 v 32 months; P =.021). We conclude that SEN V is common among liver transplant recipients but does not appear to cause graft dysfunction as an isolated agent. There is a suggestion that SEN V may be associated with HCV recurrence, but we did not detect biochemical differences attributable to SEN V.
Collapse
Affiliation(s)
- E M Yoshida
- Department of Medicine, University of British Columbia, British Columbia Transplant Society, Vancouver, BC
| | | | | | | | | |
Collapse
|
120
|
Umemura T, Yeo AE, Sottini A, Moratto D, Tanaka Y, Wang RY, Shih JW, Donahue P, Primi D, Alter HJ. SEN virus infection and its relationship to transfusion-associated hepatitis. Hepatology 2001; 33:1303-11. [PMID: 11343260 DOI: 10.1053/jhep.2001.24268] [Citation(s) in RCA: 115] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
SEN virus (SEN-V) is a recently identified single-stranded, circular DNA virus. Two SEN-V variants (SENV-D and SENV-H) were assayed by polymerase chain reaction (PCR) to investigate their role in the causation of transfusion-associated non-A to E hepatitis. The incidence of SEN-V infection after transfusion was 30% (86 of 286) compared with 3% (3 of 97) among nontransfused controls (P < .001). Transfusion risk increased with the number of units transfused (P < .0001) and donor-recipient linkage for SEN-V was shown by sequence homology. The prevalence of SEN-V in 436 volunteer donors was 1.8%. Among patients with transfusion-associated non-A to E hepatitis, 11 of 12 (92%) were infected with SEN-V at the time of transfusion compared with 55 of 225 (24%) identically followed recipients who did not develop hepatitis (P < .001). No effect of SEN-V on the severity or persistence of coexistent hepatitis C virus (HCV) infection was observed. In 31 infected recipients, SEN-V persisted for greater than 1 year in 45% and for up to 12 years in 13%. SEN-V-specific RNA (a possible replicative intermediate) was recovered from liver tissue. In summary, SENV-D and -H were present in nearly 2% of US donors, and were unequivocally transmitted by transfusion and frequently persisted. The strong association of SEN-V with transfusion-associated non-A to E hepatitis compared with controls raises the possibility, but does not establish that SEN-V might be a causative agent of posttransfusion hepatitis. The vast majority of SEN-V-infected recipients did not develop hepatitis.
Collapse
Affiliation(s)
- T Umemura
- The Department of Transfusion Medicine, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892-1184, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
121
|
Grenda R. [Patients on dialysis as renal graft recipients]. Pol Merkur Lekarski 2001; 10:300-2. [PMID: 11434186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
Many clinical aspects associated with chronic uraemia and long-term dialysis therapy may determine both the qualification for renal transplantation and post-transplant outcome. These include dialysis access, severe hyperparathyroidism, inadequate or excessive erythropoietin production, heart failure, viral hepatitis, defects of urinary tract and malnutrition. Some of them delay the qualification for transplant, the other on contrary make the need for transplantation very urgent. Selected aspects are discussed in this paper.
Collapse
Affiliation(s)
- R Grenda
- Klinika Nefrologii i Transplantacji Nerek Instytutu Centrum Zdrowia Dziecka w Warszawie
| |
Collapse
|
122
|
Saha D, Agarwal SK. Hepatitis and HIV infection during haemodialysis. J Indian Med Assoc 2001; 99:194-9, 203, 213. [PMID: 11666025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
Viral hepatitis and human immunodeficiency virus (HIV) infection are important causes of mortality and morbidity in patients treated by haemodialysis (HD). Both are further promoted by the characteristic immunological dysfunction that develops in renal failure and interferes with the patient's ability to eliminate these viruses. The hepatotropic viruses A through G remain the causative agents in 60 to 80% of hepatitis. But, as far as HD is concerned, hepatitis B virus (HBV) and hepatitis C virus (HCV) are the two most important organisms responsible for almost all the patients' morbidity. In HD, both patients as well as staff are at a high risk of acquiring hepatitis B infection. The prevalence of HBV in the dialysis population in India is reported to range between 3.4% and 42%. The acute course of the infection is often anicteric and peak transaminase concentration is significantly less than in patients with normal renal function. Up to 60% of dialysis patients with HBV infection develop chronic hepatitis with persistence of hepatitis B surface antigen (HBsAg) and infectivity. The risk of transmission of HBV infection due to blood from one patient to another is mostly because of inadequate precautions taken by the dialysis staff. Combined therapy with interferon (6-10 million units) three times a week and lamivudine (100-300 mg/day) would be more effective in controlling viral replication. The most important modality for prevention of HBV infection is induction of immunity by hepatitis B vaccination. Administration of 40 microg doses at months 0, 1, 2 and 6 is the most rapid immunogenic schedule. The prevalence of HCV in HD patients ranges from 6% in the United Kingdom to 60% in Poland and Eastern Europe, 8-36% in North America. HD patients in different parts of India exhibit high anti-HCV positivity (12.1%, 45.2%, 33.3% and 41.9%) in various studies. The incidence and prevalence of HCV infection among patients on dialysis in developed countries are steadily declining because of (i) reduction in post-transfusion HCV infection, (ii) infection control measures to prevent nosocomial infection. Among HD patients with HCV infection, serum alanine aminotransferase (ALT, SGPT) levels are elevated in only 4 to 67% patients who are positive for anti-HCV, in only 12 to 31% patients with HCV RNA and only in one-third of those with biopsy proven hepatitis. Number of blood transfusion, duration of HD treatment, and mode of dialysis are important risk factors. Patient to patient transmission of HCV occurs in HD units by needle stick injury, breakdown in standard infection control practices, physical proximity to an infected patient, dialysis machines, dialysis membranes and HD ultrafiltrate and reprocessing of dialyser. The prevalence of HIV infection in dialysis populations varies according to different countries and geographic areas, 0% and 13% in 1990 and 1995 respectively. There was no evidence of transmission within the centre transmission, from patient to patient or patient to staff. Antiretroviral therapy is the corner-stone of the HIV infection in end stage renal disease (ESRD). Most commonly, zidovudine (AZT) has been used in these patients. Currently recommended dose of 200 mg three times a day is probably safe in these patients.
Collapse
Affiliation(s)
- D Saha
- Department of Nephrology, AIIMS, New Delhi
| | | |
Collapse
|
123
|
Chorba TL, Holman RC, Clarke MJ, Evatt BL. Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States. Am J Hematol 2001; 66:229-40. [PMID: 11279632 DOI: 10.1002/ajh.1050] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Because of changes in factor replacement therapy and in treatment of human immunodeficiency virus (HIV) infection, we examined death record data for persons with hemophilia A in the United States to evaluate effects of HIV infection on age and causes of death. Multiple cause-of-death data from 1968 through 1998 were examined to assess death rates for persons with hemophilia A. ICD-9 coded causes of death from 1979 through 1998 were examined to assess long-term trends. From 1979 through 1998, 4,781 deaths among persons with hemophilia A were reported, of which 2,254 (47%) had HIV-related disease listed as a cause of death. In the late 1980s, mortality among persons with hemophilia A increased markedly, and the age-adjusted death rate peaked at 1.5 per 1,000,000 population in 1992. Median age at death decreased from 55 years in 1979-1982 to 40.5 years in 1987-1990, and increased to 46 years in 1995-1998. In the period 1995-1998, the median age of hemophilia A decedents with HIV-related disease was 33 years, compared to 72 years for those without HIV-related disease; the most frequently listed causes of death for those without HIV-related disease were hemorrhagic and circulatory phenomena; the most frequently listed for those with HIV-related disease were diseases of liver and the respiratory system. From 1995 to 1998, hemophilia A-associated deaths decreased by 41%, with a 78% decrease among those who had HIV-related disease. Although HIV infection has adversely effected mortality for persons with hemophilia A, the marked recent decrease in the death rate among persons with hemophilia A appears to reflect advances in care for those with HIV-related disease and is consistent with a decline in HIV mortality observed in the general population.
Collapse
Affiliation(s)
- T L Chorba
- Division of Immunologic, Oncologic, and Hematologic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, Atlanta, Georgia, USA.
| | | | | | | |
Collapse
|
124
|
Villela Nogueira CA, Nogueira SA, Nogueira CN, Coelho HS, Ketema F, Edelman DC, Lambert JS, Constantine NT. The incidence of GB virus C / hepatitis G virus infection in Brazilian patients who received blood transfusion during cardiac surgery. J Med Virol 2001; 63:237-41. [PMID: 11170063 DOI: 10.1002/1096-9071(200103)63:3<237::aid-jmv1006>3.0.co;2-o] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The incidence of GBV-C/hepatitis G virus (GBV-C/HGV) infection after blood transfusion is unknown in Brazil. Many studies have so far addressed its relationship with blood transfusion, but its association with liver disease was not confirmed. A prospective study was carried out between 1996 and 1999 in Rio de Janeiro. Ninety three patients who received blood transfusion during cardiac surgery were followed for six months and blood samples were drawn before and after surgery to determine antibodies to GBV-C/hepatitis G virus (anti-HGenv) using a step sandwich immunoassay and GBV-C/HGV-RNA using reverse transcriptase polymerase chain reaction. The alanine aminotransferase (ALT) levels were serially determined as well as clinical data compiled related to hepatitis. Prior to surgery, anti-HGenv was present in 35.5% (33/93) of patients and 4.3%(4/93) were found to be viremic. Seroconversion following transfusion was observed in 9 patients and 4 additional individuals became viremic for a total incidence of 23% (13/56). Six months after blood transfusion, only 4 of those nine patients previously antibody positive still had anti-HGenv detectable in serum. No patients had clinical or laboratory evidence of acute hepatitis and no correlation was found with GBV-C/HGV infection and number of blood units transfused (p = 0.37). This study highlights the importance of using both HGV-RNA PCR and anti-HGenv to accurately estimate the magnitude of GBV-C/HGV infection. The observed high prevalence and incidence rates show that this infection is common in Brazil; however, no clinical or biochemical evidence of liver disease was demonstrated in the period of study and longer longitudinal observation is needed to define any pathogenic effect.
Collapse
Affiliation(s)
- C A Villela Nogueira
- Hospital Universitário Clementino Fraga Filho e Faculdade de Medicina da Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
| | | | | | | | | | | | | | | |
Collapse
|
125
|
|
126
|
Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CM, Buskell ZJ, Ishak KG, Iber FL, Toro D, Samanta A, Koretz RL, Perrillo RP, Goodman ZD, Knodell RG, Gitnick G, Morgan TR, Schiff ER, Lasky S, Stevens C, Vlahcevic RZ, Weinshel E, Tanwandee T, Lin HJ, Barbosa L. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001; 33:455-63. [PMID: 11172349 DOI: 10.1053/jhep.2001.21905] [Citation(s) in RCA: 243] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Persons with non-A, non-B hepatitis (cases) identified in 5 transfusion studies in the early 1970s have been followed ever since and compared for outcome with matched, transfused, non-hepatitis controls from the same studies. Previously, we reported no difference in all-cause mortality but slightly increased liver-related mortality between these cohorts after 18 years follow-up. We now present mortality and morbidity data after approximately 25 years of follow-up, restricted to the 3 studies with archived original sera. All-cause mortality was 67% among 222 hepatitis C-related cases and 65% among 377 controls (P = NS). Liver-related mortality was 4.1% and 1.3%, respectively (P =.05). Of 129 living persons with previously diagnosed transfusion-associated hepatitis (TAH), 90 (70%) had proven TAH-C, and 39 (30%), non-A-G hepatitis. Follow-up of the 90 TAH-C cases revealed viremia with chronic hepatitis in 38%, viremia without chronic hepatitis in 39%, anti-HCV without viremia in 17%, and no residual HCV markers in 7%. Thirty-five percent of 20 TAH-C patients biopsied for biochemically defined chronic hepatitis displayed cirrhosis, representing 17% of all those originally HCV-infected. Clinically evident liver disease was observed in 86% with cirrhosis but in only 23% with chronic hepatitis alone. Thirty percent of non-A, non-B hepatitis cases were unrelated to hepatitis viruses A,B,C, and G, suggesting another unidentified agent. In conclusion, all-cause mortality approximately 25 years after acute TAH-C is high but is no different between cases and controls. Liver-related mortality attributable to chronic hepatitis C, though low (<3%), is significantly higher among the cases. Among living patients originally HCV-infected, 23% have spontaneously lost HCV RNA.
Collapse
Affiliation(s)
- L B Seeff
- The Veterans Affairs Medical Centers, Washington, DC, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
127
|
Schröter M, Feucht HH, Zöllner B, Schäfer P, Laufs R. Prevalence of a novel DNA virus (TTV) among patients on maintenance hemodialysis. Nephron Clin Pract 2001; 87:139-42. [PMID: 11244308 DOI: 10.1159/000045902] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND/AIMS A recently detected DNA virus (TTV) has been assumed to be responsible for posttransfusion hepatitis in humans. Until now it is unclear whether patients on maintenance hemodialysis are at increased risk of acquiring TTV. METHODS Serum samples derived from 143 chronically hemodialyzed patients were examined for TTV viremia by nested PCR. All serum specimens were also investigated for viremia and for the presence of antibodies of hepatitis C virus (HCV) and GB virus C/hepatitis G virus (GBV-C/HGV) by PCR and serological assays, respectively. RESULTS The prevalence of TTV was determined to be 18.8% (n = 27), for HCV a prevalence of 15.4% (n = 22) and for GBV-C/HGV of 8.4% (n = 12) could be demonstrated. Parallel infection by TTV and HCV was detected in only 1.4% (n = 2) of the patients. In no serum sample could TTV and GBV-C/HGV be detected in parallel. None of the solely TTV-viremic individuals had clinical or biochemical signs of liver disease. CONCLUSION From our data we conclude that TTV viremia is widespread among hemodialysis patients and can be detected in 18.8%. Since no viremic patient had clinical or biochemical signs of liver disease, the hepatitis-inducing capacity of TTV remains unclear.
Collapse
Affiliation(s)
- M Schröter
- Institut für Medizinische Mikrobiologie und Immunologie, Universitäts-Krankenhaus Eppendorf, Hamburg, Deutschland
| | | | | | | | | |
Collapse
|
128
|
Trotter JF. Cancer surveillance following orthotopic liver transplantation. Gastrointest Endosc Clin N Am 2001; 11:199-214. [PMID: 11175982] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
With the success of liver transplantation, the number of recipients continues to grow each year. Many of these patients have an increased risk for gastrointestinal malignancies. This article provides a rational basis for surveillance of gastrointestinal malignancies in the liver transplant recipient.
Collapse
Affiliation(s)
- J F Trotter
- Division of Gastroenterology/Hepatology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA.
| |
Collapse
|
129
|
Zhuang H, Li K, Zhu W, Tang R, Li S, Zhai Q, Jiang J, Liu J, Yao Z. [Etiological study on patients with seronegative viral hepatitis]. Zhonghua Nei Ke Za Zhi 2000; 39:801-4. [PMID: 11798538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
OBJECTIVE To investigate the etiology of hepatitis patients who were seronegative for viral hepatitis A through E. METHODS By using PCR, HBV DNA, HCV RNA, HEV RNA and HGV RNA were detected in sera of 104 patients with seronegative viral hepatitis. The partial nucleotide sequences of 2 HCV and 17 HEV isolates were analysed by direct sequencing. RESULTS Among the 104 patients with seronegative viral hepatitis, the positive rates of HBV DNA, HCV RNA, HEV RNA and HGV RNA were 29.8%, 3.8%, 22.1% and 7.7%, respectively, with only 38 cases (36.6%) negative for the genome of all known hepatitis viruses. CONCLUSION In addition to serological tests, the polymerase chain reaction of all known hepatitis viruses should be used to make the diagnosis of non-A - E hepatitis.
Collapse
Affiliation(s)
- H Zhuang
- Department of Microbiology, Beijing Medical University, Beijing 100083, China
| | | | | | | | | | | | | | | | | |
Collapse
|
130
|
|
131
|
|
132
|
Abstract
The liver is a common site of pathology in HIV-infected patients. In patients with controlled HIV and minimal immunosuppression, infection with hepatitis viruses is common owing to the risk factors of sexual transmission or parenteral drug use. In patients with AIDS, the liver is a common site of lymphohematogenous dissemination of several infectious pathogens. A thorough diagnostic approach leads to a diagnosis of most hepatobiliary processes. The therapeutic nihilism that has surrounded hepatic disease, including viral hepatitis, is unwarranted, because treatment of the underlying HIV and the hepatic process may improve the quality of life and longevity of these patients.
Collapse
Affiliation(s)
- M A Poles
- Division of Digestive Diseases, Center for HIV and Digestive Diseases, University of California, Los Angeles, School of Medicine, USA
| | | |
Collapse
|
133
|
Ness PM. Transfusion medicine: an overview and update. Clin Chem 2000; 46:1270-6. [PMID: 10926921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
The discovery of AIDS in the 1980s and its rapid evolution as a major concern for physicians and their patients have led to many questions about the safety of the blood supply. The attention placed on AIDS has led to new discoveries and technologies to reduce the risk of other transfusion complications such as hepatitis, bacterial contamination, and transfusion-associated graft-vs-host disease. Concerns about blood safety have focused much attention on alternative blood transfusion strategies such as autologous blood, viral inactivation, and artificial blood substitutes. This review describes the transfusion medicine delivery system in the United States, with special emphasis on evolving developments and their implications for the discipline of chemical pathology.
Collapse
Affiliation(s)
- P M Ness
- Transfusion Medicine Division, Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA.
| |
Collapse
|
134
|
Maling B. Viral hepatitis and bleeding disorders. Haemophilia 2000; 6 Suppl 1:46-51. [PMID: 10982268 DOI: 10.1046/j.1365-2516.2000.00047.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- B Maling
- Hemophilia Foundation of Michigan, USA
| |
Collapse
|
135
|
Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V, Quiros-Roldan E, Zanini B, Casari S, Carosi G. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000; 24:211-7. [PMID: 10969344 DOI: 10.1097/00126334-200007010-00003] [Citation(s) in RCA: 98] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
We undertook this study to assess the association between the various potential causes of liver disease in HIV-seropositive patients and mortality due to liver failure. Three hundred and eight in-hospital deaths were observed from 1987 to December 1995 in a prospectively followed cohort of 1894 HIV-seropositive patients. For each study subject, clinical data were evaluated to assess whether liver failure had substantially contributed to mortality. A case control study nested in the cohort was then performed, which compared demographic and clinical variables observed at enrollment and during follow-up between patients who died for liver disease as the main or concurrent cause of death (cases) and those who died as a result of illness related to AIDS or other causes (controls). Among 308 in-hospital deaths, liver failure was found the cause of death in 35 patients (12%); in 16 cases, it was the primary cause and in 19 cases it was concurrent. Multivariate analysis showed that in-hospital liver-disease-related mortality was independently associated with hepatitis B surface antigen reactivity (odds ratio [OR], 9; 95% confidence interval [CI], 3.8-21.7) and history of alcohol abuse (OR, 2.3; 95% CI, 1-5.2). Prevention and treatment of hepatitis B virus infection and alcohol intake are management priorities in HIV-seropositive patients.
Collapse
Affiliation(s)
- M Puoti
- II Divisione di Malattie Infettive, Azienda Spedali Civili, Brescia, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
136
|
Lebensztejn DM. Is TT virus (transfusion transmitted virus) a novel hepatotropic agent causing hepatitis? Med Sci Monit 2000; 6:823-6. [PMID: 11208417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023] Open
Abstract
The author presents the review of world literature regarding the infections with TT virus (Transfusion Transmitted Virus) that was discovered in Japan in 1997.
Collapse
Affiliation(s)
- D M Lebensztejn
- IIIrd Department of Pediatric Diseases, Medical University, ul. Waszyngtona 17, 15-274, Białystok, Poland
| |
Collapse
|
137
|
Rivera M, Mateos ML, Teruel JL, Tarrago D, Rodriguez JR, Fernandez-Lucas M, Ortuño J. Prevalence of hepatitis G virus infection in a hemodialysis and a peritoneal dialysis (CAPD) population. Perit Dial Int 2000; 20:470-1. [PMID: 11007381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023] Open
|
138
|
O'Connor JA. Acute and chronic viral hepatitis. Adolesc Med 2000; 11:279-92. [PMID: 10916125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
Viral hepatitis is the most common cause of acute and chronic hepatitis. The term viral hepatitis generally refers to infections resulting from one of the hepatotrophic viruses: hepatitis A, B, C, D, and E. The last 10 years have brought many important advances in understanding the epidemiology, pathogenesis, molecular biology, and immunoprophylaxis of infections caused by hepatotrophic viruses. Development of sensitive and specific immunoassays has enabled detection of specific agents. This has allowed for identification of infected patients and monitoring response to therapy. Additionally, serologic markers have allowed for isolation of contaminated blood products and a reduction in the spread of disease. The remaining challenge is the application of this knowledge to the treatment and prevention of viral hepatitis. This article explores the risk factors, epidemiology, microbiology, clinical and laboratory diagnosis, treatment, and prevention of the hepatotrophic viral infections.
Collapse
MESH Headings
- Acute Disease
- Adolescent
- Hepacivirus/immunology
- Hepacivirus/physiology
- Hepatitis A/diagnosis
- Hepatitis A/epidemiology
- Hepatitis A/therapy
- Hepatitis A Virus, Human/immunology
- Hepatitis A Virus, Human/physiology
- Hepatitis B/prevention & control
- Hepatitis B/therapy
- Hepatitis B virus/immunology
- Hepatitis B virus/physiology
- Hepatitis C/epidemiology
- Hepatitis C/prevention & control
- Hepatitis C/therapy
- Hepatitis D/epidemiology
- Hepatitis D/etiology
- Hepatitis D/immunology
- Hepatitis E/diagnosis
- Hepatitis E/epidemiology
- Hepatitis E/therapy
- Hepatitis E virus/immunology
- Hepatitis E virus/physiology
- Hepatitis, Chronic/epidemiology
- Hepatitis, Chronic/etiology
- Hepatitis, Chronic/immunology
- Hepatitis, Chronic/therapy
- Hepatitis, Viral, Human/diagnosis
- Hepatitis, Viral, Human/epidemiology
- Hepatitis, Viral, Human/etiology
- Hepatitis, Viral, Human/therapy
- Humans
Collapse
Affiliation(s)
- J A O'Connor
- Division of Pediatric Sub-Specialty Services, San Antonio Military Pediatric Center, Brooke Army and Wilford Hall Medical Centers, San Antonio, Texas, USA
| |
Collapse
|
139
|
de La Rosa JM, Escobedo M. Tuberculosis and other infectious diseases in the adolescent immigrant. Adolesc Med 2000; 11:453-66. [PMID: 10916134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
Adolescent medicine physicians are frequently the initial contact for adolescents newly arriving in the U.S. and it is important that they recognize the needs of their patients. The adolescent immigrant may be encountered in a school-based health setting, private practice, community health center, or other health care settings. This article begins with a review of the categories of immigrants comprising the adolescent population. It gives an extensive review of tuberculosis among Mexican-American adolescents, detailing history, epidemiology, diagnosis, social factors, and treatment modalities. It further delineates the impact of Mexican tuberculosis control strategies on the practice of medicine in the U.S., and outlines preventive, diagnostic, and therapeutic strategies that should be followed in the adolescent immigrant. This article also reviews viral hepatitis in its multiple forms and its impact on the adolescent immigrant. It concludes by delineating prevention practices required for the adolescent immigrant and summarizes the interventions an initial contact physician should undertake upon encountering such adolescents.
Collapse
Affiliation(s)
- J M de La Rosa
- Texas Tech University Health Sciences Center-El Paso, El Paso, TX 79905, USA
| | | |
Collapse
|
140
|
|
141
|
Affiliation(s)
- H Hassan
- Department of Internal Medicine, Saint Louis University School of Medicine, Missouri 63110, USA
| | | |
Collapse
|
142
|
Hyams KC. Chronic liver disease among U.S. military patients: the role of hepatitis C and G virus infection. Mil Med 2000; 165:178-9. [PMID: 10741077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023] Open
Abstract
Thirty-nine patients with chronic liver disease who were being evaluated in a U.S. military treatment facility were tested for antibody to hepatitis C virus (anti-HCV) and for hepatitis G virus (HGV) RNA by reverse transcriptase-polymerase chain reaction. Serum samples from 20 patients (51%) were positive for anti-HCV by immunoblot assay. HGV RNA was found in the sera of only two patients, both of whom were also positive for anti-HCV. HGV appears to have a limited role in causing chronic liver disease in this population of military patients, many of whom had traveled outside the United States. However, HCV infection was commonly associated with chronic hepatitis and cirrhosis, as in civilian patients.
Collapse
MESH Headings
- Adult
- Chronic Disease
- Female
- Flaviviridae/immunology
- Hepatitis Antibodies/blood
- Hepatitis C Antibodies/blood
- Hepatitis C, Chronic/blood
- Hepatitis C, Chronic/etiology
- Hepatitis C, Chronic/immunology
- Hepatitis C, Chronic/virology
- Hepatitis, Chronic/blood
- Hepatitis, Chronic/etiology
- Hepatitis, Chronic/immunology
- Hepatitis, Chronic/virology
- Hepatitis, Viral, Human/blood
- Hepatitis, Viral, Human/etiology
- Hepatitis, Viral, Human/immunology
- Hepatitis, Viral, Human/virology
- Humans
- Liver Diseases/virology
- Male
- Middle Aged
- Military Personnel/statistics & numerical data
- Risk Factors
- Travel
- United States
Collapse
Affiliation(s)
- K C Hyams
- Naval Medical Research Center, Bethesda, MD 20889-5607, USA
| |
Collapse
|
143
|
Abstract
BACKGROUND Hepatitis G virus (HGV), also known as GB virus C, is a newly discovered Flavivirus that is transmissible by blood transfusion and other possible routes. OBJECTIVE To study the risk of sexual transmission of HGV in female sexual partners of men with hemophilia (n = 161 couples). METHODS Blood samples obtained from 11 medical centers were analyzed for (1) HGV RNA by polymerase chain reaction; (2) antibodies to HGV by enzyme immunoassay; and (3) other viruses and T-cell counts by routine laboratory tests. Subjects completed a questionnaire that assessed sexual intercourse frequency, number of sexual partners, condom usage, sexually transmitted diseases, illicit drug usage, and needlestick or broken-glass injuries. RESULTS The HGV infection (RNA +/- antibody positive) prevalence was 48% among men and 21% among women. Prevalence of hepatitis C virus, hepatitis B virus, and HIV among men was 99%, 94%, and 86%, compared with 3%, 11%, and 12% among women, respectively. The odds ratio for HGV infection for women with an HGV-positive male sexual partner was 2.14 (P = 0.06) without adjustment, and 2.77 (P = 0.03) with adjustment for other variables, none of which were independently significant. CONCLUSION These results suggest a low level of HGV sexual transmission.
Collapse
MESH Headings
- Antibodies, Viral/analysis
- Austria
- Female
- Flaviviridae/genetics
- Flaviviridae/immunology
- Greece
- Hemophilia A/complications
- Hepatitis, Viral, Human/blood
- Hepatitis, Viral, Human/etiology
- Hepatitis, Viral, Human/immunology
- Hepatitis, Viral, Human/transmission
- Humans
- Immunoenzyme Techniques
- Logistic Models
- Male
- Polymerase Chain Reaction
- RNA, Viral/analysis
- Risk Factors
- Seroepidemiologic Studies
- Sexual Behavior
- Sexual Partners
- Sexually Transmitted Diseases/blood
- Sexually Transmitted Diseases/etiology
- Sexually Transmitted Diseases/immunology
- Sexually Transmitted Diseases/transmission
- Substance Abuse, Intravenous/complications
- Surveys and Questionnaires
- United States
Collapse
Affiliation(s)
- A E Yeo
- Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA
| | | | | | | | | |
Collapse
|
144
|
Affiliation(s)
- M Pellisé
- Department of Pathology, IDIBAPS, Hospital Clínic, University of Barcelona, Spain
| | | |
Collapse
|
145
|
Raiola AM, Van Lint MT, Lamparelli T, Gualandi F, Benvenuto F, Figari O, Mordini N, Berisso G, Bregante S, Frassoni F, Bacigalupo A. Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. Haematologica 2000; 85:59-62. [PMID: 10629593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023] Open
Abstract
BACKGROUND AND OBJECTIVE Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disease of the hemopoietic stem cell (HSC) characterized by intravascular hemolysis and increased risk of venous thrombosis. There are different therapeutic approaches for PNH which do not cure the disease, but can decrease its complications. Allogeneic bone marrow transplantation (BMT) may cure PNH. We reports here our experience of seven PNH patients who underwent allogeneic BMT. DESIGN AND METHODS Between January 1991 and January 1999 seven patients with PNH, aged 23 to 37, were transplanted with unmanipulated bone marrow from HLA identical siblings. Median time from diagnosis to BMT was 2.5 years (range: 1-16). All patients were transfusion-dependent and had received various treatments before BMT: steroids, vitamins, cyclosporin A (CyA), growth factors. One patient had also been treated with anti-thymocyte globulin. One patient was HbsAg positive and one anti-HCV positive. At the time of BMT the median value of hemoglobin (Hb) was 9 g/dL (range 6.5-11), white blood cells 5&10(9)/L (range: 2.9-7.7), platelets 97&10(9)/L (range: 31-355), LDH: 2726 U/L. The conditioning regimen was cyclophosphamide (160 mg/kg) and busulfan (10-14 mg/kg), followed by unmanipulated bone marrow (median of 5&10(8) cells/kg) and CyA (+MTX in two patients) for prophylaxis of graft-versus-host disease (GvHD). RESULTS All seven patients are alive, full chimeras, with complete hematologic recovery and no evidence of PNH, at a median follow up of 51 months post-BMT (6-103). Time to achieve a granulocyte count of 0.5&10(9)/L, platelets 30&10(9)/L and Hb 10 g/dL was respectively 16, 19 and 22 days. Acute GvHD was limited or mild in six patients, and severe in one. Chronic GvHD was extensive in two patients. INTERPRETATION AND CONCLUSIONS This study confirms that HLA identical sibling BMT is an effective therapeutic option for PNH, also in the hemolytic phase of the disease: it also suggests that HBV and HCV infections are not an absolute contraindication.
Collapse
Affiliation(s)
- A M Raiola
- Dipartimento di Ematologia, Ospedale San Martino, largo R. Benzi 10, 16132 Genoa, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
146
|
Minamiguchi S, Sakurai T, Fujita S, Okuno T, Haga H, Mino M, Kanehira K, Matsushiro H, Nakashima Y, Inomata Y, Tanaka K, Yamabe H. Living related liver transplantation: histopathologic analysis of graft dysfunction in 304 patients. Hum Pathol 1999; 30:1479-87. [PMID: 10667427 DOI: 10.1016/s0046-8177(99)90171-5] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
Between June 1990 and August 1997, 304 mainly pediatric patients underwent a total of 311 orthotopic living related liver transplantations (LRLTs) under tacrolimus immunosuppression at Kyoto University Hospital. Congenital biliary atresia was the most common underlying disease. The donor was a parent, and the left lateral segments were used as grafts in most cases. The average number of loci of HLA-A, -B, and -DR mismatches between the donor and the recipient were 2.1. Forty-three transplants were ABO-incompatible. Liver histology at the time of abnormal liver function after transplantation was analyzed. Preservation injury was rare and mild. Acute cellular rejection (ACR) occurred in 36% of transplants during the first 6 months. Average rejection activity index (the Banff schema) was 4.2 and severe rejection was rarely seen. The number of mismatching HLA loci and immunosuppression regimens affected the incidence of ACR. Chronic rejection (CR) occurred in 2% of transplants. Concerning humoral rejection, no hyperacute rejection was seen. However, hepatic artery thrombosis (delayed hyperacute rejection) was seen in an ABO-incompatible transplant. Acute hepatitis, including those related to cytomegalovirus and Epstein-Barr virus, occurred in 17% of transplants. Chronic hepatitis, including hepatitis B and C, developed in 3%. Acute or chronic cholangitis occurred in 16%, and a significantly higher incidence of cholangitis was found in ABO-incompatible transplants. Posttransplantation lymphoproliferative disease developed in 2%. In LRLT, milder preservation injury and less frequent ACR and CR were suggested, probably because of the short cold-ischemia time and the advantages of HLA histocompatibility, respectively.
Collapse
Affiliation(s)
- S Minamiguchi
- Department of Transplantation and Immunology, Kyoto University Hospital, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
147
|
Lian Y, Wu W, Shi Y. [Preliminary study on relationship between different viral pathogenesis and disease prognosis in patients with severe viral hepatitis]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 1999; 13:355-7. [PMID: 12759976] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
Abstract
OBJECTIVE To study the relationship between different viral pathogenesis and disease prognosis in severe viral hepatitis. METHODS Different viral pathogenesis of 87 dead and live cases with severe viral hepatitis were compared. RESULTS Total mortality of 87 patients with severe hepatitis was 74.71% (65/87), total prevalence of HBV infection alone in these patients was 41.38% (36/87). The detection rates of HBV infection alone and superinfection of different hepatitis viruses in 68 patients with chronic severe hepatitis (CSH) were 41.18% (28/68) and 58.82% (40/68) respectively. The prevalences of superinfection of HBV and HEV or HAV and superinfection of HBV and CMV in patients with CSH were 27.94% (19/68) and 10.29 (7/68) respectively. The mortality of superinfection of HBV and CMV (85.71%) was the highest, followed by HBV infection alone (77.78%). In addition, the prevalence and mortality of HBV infection alone in 19 patients with acute or subacute severe hepatitis was the highest. CONCLUSION HBV, HEV or HAV infection alone was the main viral pathogenesis of severe hepatitis. Superinfection of different viruses in patients with CSH was the most common viral infection type. An unpromising prognosis of superinfection of HBV and CMV in CSH is noted.
Collapse
Affiliation(s)
- Y Lian
- Institute of Infectious Diseases, Guangzhou 8th People's Hospital, Guangzhou 510060
| | | | | |
Collapse
|
148
|
Aksu K, Kabasakal Y, Sayiner A, Keser G, Oksel F, Bilgiç A, Gümüşdiş G, Doganavşargil E. Prevalences of hepatitis A, B, C and E viruses in Behçet's disease. Rheumatology (Oxford) 1999; 38:1279-81. [PMID: 10587560 DOI: 10.1093/rheumatology/38.12.1279] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
OBJECTIVE To determine whether Behçet's disease (BD), being a systemic vasculitis of unknown aetiology, is associated with hepatitis viruses (HAV, HBV, HCV and HEV). METHODS In addition to 124 patients [male:female (M/F): 73/51], all fulfilling the diagnostic criteria of the International Study Group for BD (1991), 14 patients with systemic necrotizing vasculitis (M/F: 7/7), 47 patients with ankylosing spondylitis (M/F: 36/11) and 51 healthy controls (M/F: 22/29) were also included in this study. Serological markers of four different types of hepatitis (anti-HAV IgM, total anti-HAV, HBsAg, anti-HBs, total anti-HBc, anti-HBc IgM, anti-HCV and anti-HEV) were studied in all cases. RESULTS There was no difference between the groups with respect to HAV, HCV and HEV serologies. Anti-HBs positivity was observed less frequently in BD compared with healthy controls and systemic vasculitis (P<0.05). CONCLUSION Serological evidence of previous HAV, HCV and HEV infections was not significantly different between Behçet's patients and other groups. However, previous HBV infection was found in a significantly lower number of BD patients as compared with healthy controls and systemic vasculitic patients.
Collapse
Affiliation(s)
- K Aksu
- Division of Rheumatology, Department of Internal Medicine and Clinical Microbiology, Ege University School of Medicine, Bornova, Izmir, Turkey
| | | | | | | | | | | | | | | |
Collapse
|
149
|
Colombatto P, Brunetto MR, Kansopon J, Oliveri F, Maina A, Aragon U, Bortoli ML, Scatena F, Baicchi U, Houghton M, Bonino F, Weiner AJ. High prevalence of G1 and G2 TT-virus infection in subjects with high and low blood exposure risk: identification of G4 isolates in Italy. J Hepatol 1999; 31:990-6. [PMID: 10604571 DOI: 10.1016/s0168-8278(99)80310-9] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Abstract
BACKGROUND/AIMS A non-enveloped single-stranded DNA virus (TTV) was detected in Japanese patients with fulminant hepatitis (47%) and chronic liver disease of unknown etiology (46%) more frequently than in blood donors (12%). Subsequent studies, however, questioned the association of TTV with liver disease. We further investigated the role of this novel virus in liver diseases. METHODS We tested 106 patients and 102 blood donors for TTV by polymerase chain reaction using conserved region primers. RESULTS TTV DNA was found in 19 of 102 volunteer blood donors (18.6%) and in 27 of 106 patients with liver disease (25.5%): 10 of 28 chronic hepatitis B (35.7%), 9 of 28 chronic hepatitis C (32.1%) and 8 of 50 (16%) cryptogenic liver disease patients. Previous interferon treatment was not associated with a significantly lower prevalence of TTV infection. TTV prevalence was higher in patients with blood exposure (42.8%, 6/14) than in patients without risk factors (21.4%, 18/84). Four of five patients (80%) with HBV familial infection and without blood exposure were also TTV positive. Partial nucleotide sequences from 3 Italian isolates diverged more than 30% from the 2 prototype genotypes G1 and G2 and were 88% homologous to the recently described genotype G4. CONCLUSIONS G1 and G2 TTV are common in Italy and in the USA in liver disease patients and in blood donors. The prevalence is high in patients with blood exposure but also in subjects without risk factors; other routes of transmission should therefore be considered.
Collapse
Affiliation(s)
- P Colombatto
- Gastroenterology and Hepatology Unit, Spedali Riuniti Santa Chiara, Azienda Ospedaliera Pisana, Cisanello, Pisa, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
150
|
Martin P, Fabrizi F, Dixit V, Brezina M, Gerosa S, Russell J, Conrad A, Gitnick G. Epidemiology and natural history of hepatitis G virus infection in chronic hemodialysis patients. Am J Nephrol 1999; 19:535-40. [PMID: 10575179 DOI: 10.1159/000013515] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
UNLABELLED Patients on chronic hemodialysis (HD) have recently been identified as having a high prevalence of hepatitis G virus (HGV) infection. The clinical significance of HGV in this population remains unclear, with no data available as to the acquisition and natural history of HGV infection in this group. AIMS To assess the prevalence and risk factors of HGV in a large cohort of chronic HD patients, and to evaluate the incidence and clinical consequences of HGV over time in this population. METHODS Paired sera from 292 patients undergoing chronic HD treatment in four units in the Los Angeles area were tested for HGV RNA before and after they had been on HD for a mean period of 9.7 +/- 1.9 months. HGV was tested by a single-step RT-PCR using two couples of primers located in two different portions (5'UTR, NS5a) of the genome. The amplified products were detected by hybridization with 5' biotin-labeled probes specific for each region. RESULTS At study entry there were 50 HGV RNA-positive patients, thus the HGV prevalence was 17% (50/292). The multivariate analysis by ordinal logistic regression model showed association (p = 0.0013) between HGV RNA and the location of patients among the HD units. No other significant associations were observed. Three (3/50 = 6%) HGV RNA-positive patients at study entry and 3 (3/41 = 7%) at the end of the follow-up showed a mild increase of alanine aminotransferase (ALT) activity in absence of other apparent causes of liver damage. 35 (70%) out of 50 HGV viremic patients had persistently detectable viremia during the study period; 15 (30%) had non-persistently detectable HGV RNA in the second serum specimen. There was no significant difference between the patients with persistently detectable HGV RNA and those who showed non-persistently detectable HGV viremia with regard to demographic, clinical or virological features. Six patients without detectable HGV viremia at the start of the study showed de novo HGV infection during the follow-up, thus the HGV incidence was 3.07% per year. These individuals did not simultaneously acquire HBV or HCV markers; de novo HGV infection was not associated with other demographic, clinical or virological features. One (16.7%) out of 6 individuals with HGV acquisition had persistently raised ALT levels and chronic HBsAg positivity. The prevalence of HGV was 14% (41/292) at the end of the observation period. CONCLUSIONS The prevalence of HGV in our HD population was high; HGV positivity was strongly associated with the location of HD patients among the units; some HD individuals with current HGV infection showed biochemical signs of liver disease without other apparent causes. De novo acquisition of HGV occurred within HD units in the absence of evident parenteral risk factors for HGV other than their presence in the HD environment. A large portion of HGV viremic patients showed non-persistently detectable HGV viremia during the study. Acquisition of HGV was not associated with a rise in ALT activity unlike prior experience with de novo HCV in HD patients. Further investigations are warranted to explain the modes of HGV acquisition and the clinical significance of HGV in th HD population.
Collapse
MESH Headings
- Chronic Disease
- Cross Infection/epidemiology
- Cross Infection/etiology
- Cross Infection/transmission
- Cross Infection/virology
- DNA Primers/chemistry
- Disease Transmission, Infectious
- Female
- Flaviviridae/genetics
- Hepatitis, Viral, Human/epidemiology
- Hepatitis, Viral, Human/etiology
- Hepatitis, Viral, Human/transmission
- Hepatitis, Viral, Human/virology
- Humans
- Incidence
- Kidney Failure, Chronic/therapy
- Los Angeles/epidemiology
- Male
- Middle Aged
- Prevalence
- RNA, Viral/analysis
- Renal Dialysis/adverse effects
- Reverse Transcriptase Polymerase Chain Reaction
- Risk Factors
Collapse
Affiliation(s)
- P Martin
- Department of Medicine, UCLA School of Medicine, Los Angeles, CA, USA
| | | | | | | | | | | | | | | |
Collapse
|